CheckMate 012: Safety and Efficacy of First-Line Nivolumab and Ipilimumab in Advanced NSCLC

被引：10
|
作者：
Antonia, Scott J. [1 ]
Gettinger, Scott N. [2 ]
Goldman, Jonathan [3 ]
Brahmer, Julie [4 ]
Borghaei, Hossein [5 ]
Chow, Laura Q. [6 ]
Ready, Neal E. [7 ]
Gerber, David E. [8 ]
Juergens, Rosalyn [9 ]
Shepherd, Frances [10 ]
Laurie, Scott A. [11 ]
Young, Tina [12 ]
Geese, William J. [12 ]
Agrawal, Shruti [12 ]
Li, Xuemei [12 ]
Hellmann, Matthew D. [13 ]
机构：
[1] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[2] Yale Comprehens Canc Ctr, New Haven, CT USA
[3] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA
[4] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA
[5] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA
[6] Univ Washington, Seattle, WA 98195 USA
[7] Duke Univ, Med Ctr, Durham, NC USA
[8] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA
[9] McMaster Univ, Juravinski Canc Ctr, Hamilton, ON, Canada
[10] Univ Toronto, Princess Margaret Hosp, Toronto, ON, Canada
[11] Univ Ottawa, Ctr Canc, Ottawa Hosp, Ottawa, ON, Canada
[12] Bristol Myers Squibb, Princeton, NJ USA
[13] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2016年 / 11卷 / 11期
关键词：
D O I：
10.1016/j.jtho.2016.09.008
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ORAL01.03
引用
下载
收藏
页码：S250 / S251
页数：3
相关论文
共 50 条
  • [41] Efficacy and safety of first-line nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma: A multicenter retrospective study
    Tanaka, Toshikazu
    Hatakeyama, Shingo
    Numakura, Kazuyuki
    Kido, Koichi
    Noro, Daisuke
    Oikawa, Masaaki
    Hosogoe, Shogo
    Tokui, Noriko
    Yamamoto, Hayato
    Narita, Shintaro
    Ito, Hiroyuki
    Yoneyama, Takahiro
    Hashimoto, Yasuhiro
    Kawaguchi, Toshiaki
    Habuchi, Tomonori
    Ohyama, Chikara
    INTERNATIONAL JOURNAL OF UROLOGY, 2020, 27 (12) : 1095 - 1100
  • [42] Efficacy and safety of nivolumab in first-line or further treatment of advanced metastatic biliary tract cancer.
    Gou, Miaomiao
    Zhang, Yong
    Si, Haiyan
    Dai, Guanghai
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [43] CheckMate 169: Safety/Efficacy of Nivolumab in Canadian Pretreated Advanced NSCLC (including Elderly and PS 2) Patients
    Juergens, R.
    Chu, Q.
    Rothenstein, J.
    De Angelis, F.
    Banerji, S.
    Marquis, K.
    Sauciuc, D.
    Begin, P.
    Finn, N.
    Hirsh, V.
    Faghih, A.
    Yun, J.
    Li, A.
    Acevedo, A.
    Musallam, L.
    Cheema, P.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2426 - S2427
  • [44] COST-EFFECTIVENESS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB IN FIRST-LINE TREATMENT OF ADVANCED MELANOMA IN SWEDEN
    Baker, T. M.
    Paly, V. F.
    Thybo, S.
    Hultberg, M.
    Minacori, R.
    Kotapati, S.
    Sabater, J.
    VALUE IN HEALTH, 2016, 19 (07) : A730 - A731
  • [45] CHECKMATE 040: EFFICACY, HEPATIC SAFETY, AND BIOMARKERS OF NIVOLUMAB plus IPILIMUMAB COMBINATION THERAPY IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA
    Sangro, Bruno
    Hsu, Chiun
    Kang, Yoon-Koo
    Kim, Tae-You
    El-Khoueiry, Anthony
    Santoro, Armando
    Melero, Ignacio
    Kudo, Masatoshi
    Hou, Ming-Mo
    Pena, Ana Matilla
    Tovoli, Francesco
    Knox, Jennifer J.
    He, Aiwu Ruth
    El-Rayes, Bassel
    Acosta, Mirelis Rivera
    Lim, Ho-Yeong
    Neely, Jaclyn
    Zhao, Huanyu
    Anderson, Jeffrey
    Yau, Thomas
    HEPATOLOGY, 2019, 70 : 131A - 132A
  • [46] Combined ipilimumab and nivolumab first-line and after BRAF-targeted therapy in advanced melanoma
    Mason, Robert
    Dearden, Helen C.
    Nguyen, Bella
    Soon, Jennifer A.
    Smith, Jessica Louise
    Randhawa, Manreet
    Mant, Andrew
    Warburton, Lydai
    Lo, Serigne
    Meniawy, Tarek
    Guminski, Alexander
    Parente, Phillip
    Ali, Sayed
    Haydon, Andrew
    Long, Georgina V.
    Carlino, Matteo S.
    Millward, Michael
    Atkinson, Victoria G.
    Menzies, Alexander M.
    PIGMENT CELL & MELANOMA RESEARCH, 2020, 33 (02) : 358 - 365
  • [47] Long-term efficacy of combination nivolumab and ipilimumab for first-line treatment of advanced melanoma: A network meta-analysis
    Mohr, P.
    Toor, K.
    Goring, S.
    Chan, K.
    Besada, M.
    Johnson, H. M.
    Moshyk, A.
    Kotapati, S.
    ANNALS OF ONCOLOGY, 2019, 30
  • [48] Efficacy of Ipilimumab in Combination with Chemotherapy for First-Line Treatment of Advanced Lung Cancer
    Htut, T.
    Tun, A.
    Swarup, S.
    Sultan, A.
    Mogollon-Duffo, F.
    Jahan, N.
    Adhikari, N.
    Oo, Y.
    Thida, A.
    Aung, H.
    Thi, W.
    Panigrahi, K.
    Tijani, L.
    Thein, K.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S743 - S743
  • [49] Efficacy and safety of first-line combination therapy with ipilimumab plus nivolumab for metastatic renal cell carcinoma in a single institution in Japan
    Nagata, M.
    Horie, S.
    Nagaya, N.
    ANNALS OF ONCOLOGY, 2023, 34 : S1566 - S1567
  • [50] CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer
    Janjigian, Yelena Y.
    Bendell, Johanna
    Calvo, Emiliano
    Kim, Joseph W.
    Ascierto, Paolo A.
    Sharma, Padmanee
    Ott, Patrick A.
    Peltola, Katriina
    Jaeger, Dirk
    Evans, Jeffry
    de Braud, Filippo
    Chau, Ian
    Harbison, Christopher T.
    Dorange, Cecile
    Tschaika, Marina
    Le, Dung T.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (28) : 2836 - +
12345